-+ 0.00%
-+ 0.00%
-+ 0.00%

JOHNSON & JOHNSON REPORTS 73% PSA RESPONSE RATE WITH INVESTIGATIONAL PASRITAMIG-BASED IMMUNOTHERAPY COMBINATION IN ADVANCED PROSTATE CANCER

Reuters·11/08/2026 16:01:21

Please log in to view news